Sesen Bio, Inc. (SESN): Price and Financial Metrics

Sesen Bio, Inc. (SESN): $12.58

0.85 (+7.29%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add SESN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#102 of 400

in industry

SESN Price/Volume Stats

Current price $12.58 52-week high $12.58
Prev. close $0.59 52-week low $0.37
Day low $11.40 Volume 93,330
Day high $12.58 Avg. volume 1,067,298
50-day MA $0.60 Dividend yield N/A
200-day MA $0.61 Market Cap 2.56B

SESN Stock Price Chart Interactive Chart >


Sesen Bio, Inc. (SESN) Company Bio


Sesen Bio (formerly Eleven Biotherapeutics, Inc.), a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts.


SESN Latest News Stream


Event/Time News Detail
Loading, please wait...

SESN Latest Social Stream


Loading social stream, please wait...

View Full SESN Social Stream

Latest SESN News From Around the Web

Below are the latest news stories about SESEN BIO INC that investors may wish to consider to help them evaluate SESN as an investment opportunity.

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

CAMBRIDGE, Mass., March 02, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company’s Special Meeting of Stockholders (the "Special Meeting") held earlier today.

Yahoo | March 2, 2023

Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results

CAMBRIDGE, Mass., February 28, 2023--Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Yahoo | February 28, 2023

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma

CAMBRIDGE, Mass., February 21, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company’s upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023.

Yahoo | February 21, 2023

Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote "FOR" All Proposals at March 2 Special Meeting

CAMBRIDGE, Mass., February 16, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company’s upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. ISS is widely recognized as a leading independent proxy advisory firm, providing impartial analys

Yahoo | February 16, 2023

Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

CAMBRIDGE, Mass., February 16, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. ("Carisma") management team on Tuesday, February 21, 2023, at 8:00 am ET. The discussion will cover Sesen Bio’s pending merger with Carisma, as well as Carisma’s corporate strategy and clinical programs. Sesen Bio stockholders can submit questions in advance to [email protected].

Yahoo | February 16, 2023

Read More 'SESN' Stories Here

SESN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 7.52%
3-year -76.88%
5-year -37.10%
YTD N/A
2023 0.00%
2022 -25.21%
2021 -39.63%
2020 29.81%
2019 -26.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!